These ASR products utilize the company's proprietary Barcoded Magnetic Bead technology for specific detection of targeted organisms.
For use as building blocks to develop and validate tests for the diagnosis of infectious diseases, ASRs may be sold to in vitro diagnostic manufacturers, and clinical laboratories regulated under the Clinical Laboratory Improvement Amendments of 1988, as qualified to perform high complexity testing.
ASRs may also be sold to organizations that use the reagents to make tests for purposes other than providing diagnostic information to patients and practitioners, e.g., forensic, academic, research, and other nonclinical laboratories.
The primer pairs or probes coupled to BMBs are classified as ASRs, which can be used by high-complexity laboratories to develop their own laboratory developed tests.
The US Food and Drug Administration defines Analyte Specific Reagents as "antibodies, both polyclonal and monoclonal, specific receptor proteins, ligands, nucleic acid sequences, and similar reagents, which through specific binding or chemical reactions with substances in a specimen, are intended for use in a diagnostic application for identification and quantification of an individual chemical substance or ligand in biological specimens." 21 CFR 864.4020
Under 42 CFR part 493, regulated under VHA Directive 1106 (available from Department of Veterans Affairs, Veterans Health Administration, Washington, DC 20420).
Applied BioCode is an IVD manufacturer that designs, develops, and commercializes multiplex testing products.
The company has combined "digital barcodes" with immuno- and molecular chemistry to create a new, bio-inspired Barcoded Magnetic Beads technology.
The micro BMBs, about the diameter of a human hair, are tagged with immunochemistry or molecular probes, allowing the digital barcodes to be easily scanned and accurately identified up to 4,096 barcodes with no ambiguity for biological targets.
The company has FDA 510K clearances for their Respiratory 17-plex Pathogen Panel and Gastrointestinal 17-plex Pathogen Panel based on their BioCode MDx-3000 automated system.
Applied BioCode also partners with a variety of diagnostic companies with applications that include the infectious disease, autoimmune disease, allergy, gut microbiome, and veterinary markets.
Amgen's UPLIZNA receives US FDA approval
FDA grants priority review to Bristol Myers Squibb's Opdivo regimen for advanced Hodgkin lymphoma
Zydus Lifesciences enters licence and supply partnership with Formycon
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
J & D Pharmaceuticals' investigational therapy for HCC receives US FDA Orphan Drug Designation
FDA lifts partial clinical hold on Vanda Pharmaceuticals' tradipitant for motion sickness
TransThera publishes clinical results from US-based Phase 2 trial of tinengotinib in CCA
Hope Medicine wins FDA Fast Track Designation for HMI-115 in endometriosis
MED-EL cochlear implant FDA approved for children 7 months and older
Bayer launches Phase IIa trial of BAY 3401016 for Alport Syndrome